Effect of Sage Extract Supplementation on Cognitive Function in Middle-Aged Men and Women

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-60
SponsorESM Technologies, LLC

About this trial

Sage (Salvia officinalis) has been reported to have antioxidant, anti-inflammatory, and neuroprotective properties. Several studies indicate that sage supplementation can improve cognitive function. However, more research is needed. The purpose of this study is to examine how sage supplementation affects cognitive function and reaction times in middle-aged men and women.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

BMI 18.5-34.9 (inclusive) with a goal of being < 30 on average

Subject agrees to maintain their existing dietary patterns throughout the study period.

Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours before each test day.

Subject is willing and able to comply with the study protocol.

Disqualifiers

Individuals with a personal history of a psychiatric disorder.

Individuals who are determined to have liver, renal, cardiovascular, or other metabolic disease.

Current or recent (< 4 weeks) use of any dietary supplements (e.g., choline, lecithin, ginseng, ginkgo biloba, ashwagandha, Bacopa Monnieri, Paullina cupana, Rhodiola rosea, L-theanine, omega-3 fats, Prevagen, etc.), or currently prescribed medications (e.g., Adderall, Mydayis, Ritalin, Concerta, Mythylin, Provigil, Namenda), that may affect cognitive function (focus, concentration, memory, reaction time, energy, etc.).

Alcohol consumption (>2 standard alcoholic drinks/day or >10 drinks/week) or drug abuse/dependence (including regular marijuana or THC use).

Trial design

Design model

Parallel

Treatments tested in this trial

  • SageXtra

    Dietary supplement

    333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule).

  • Placebo

    Dietary supplement

    333 mg/day of methylcellulose powder in two #0 capsules.

Treatment groups

64 Participants
are divided into 2 treatment groups
Group A: ActiveExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

COMputerized Mental Performance ASsessment System (COMPASS) Test Battery

COMPASS consists of seven components including; 1) Immediate and Delayed Word Recall, 2) Delayed Word Recognition, 3) Delayed Picture Recognition, 4) Corsi Blocks Task, 5) Digit Vigilance, 6) Stroop Test and, 7) Choice Reaction Time evaluated via a computer program.

Time frame
4 weeks and 8 weeks

Secondary outcomes

1

Physical performance

Evaluation of reaction time via a computer program where the subject has to press a key on the keyboard when an area of the computer screen lights up.

Time frame
4 weeks and 8 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

ESM Technologies, LLC

Lead sponsor

Exercise & Sport Nutrition Lab, Texas A&M University

Collaborator